Pembrolizumab: tested with established drugs

245 studies: they are given beside it. Page 1 of 3. Open to participants first (35), then studies with results posted, then the rest; newest registration first within each.

A Trial of Pembrolizumab With Chemotherapy or Chemoradiotherapy in Participants From India With Different Types of Cancer (MK-3475-G44/KEYNOTE-G44)Not yet recruitingNCT07801027Phase 4 Report a problem
Pembrolizumab Adjuvant in Patients With Early-stage Triple Negative Breast Cancer With Residual Disease After Neoadjuvant Pembrolizumab Plus ChemotherapyNot yet recruitingNCT07486687Phase 3 Report a problem
Perioperative Chemotherapy and Immunotherapy for Locally Recurrent Nasopharyngeal CarcinomaNot yet recruitingNCT07129772Phase 2 Report a problem
An Open Label Phase 2 Study of Total Neoadjuvant Therapy (TNT) Consisting of FLOT With Pembrolizumab and Short Radiation for Patients With Locally Advanced Gastroesophageal Junction AdenocarcinomaRecruitingNCT07018570Phase 2 Report a problem
Optimizing Neoadjuvant Treatment Regimens for Locally Advanced Esophageal Squamous Cell CarcinomaRecruitingNCT06907602Phase 2/3 Report a problem
ctDNA to Predict Response to Chemo-Immunotherapy and Detect Minimal Residual Disease in Non-Small Cell Lung CancerRecruitingNCT06902272Phase 2 Report a problem
A Study to Evaluate Efficacy, and Safety of QL2107 Plus Chemo and Compare With Keytruda in Participants With IV nqNSCLCRecruitingNCT06754644Phase 3 Report a problem
Prospective Trial Assessing Real World Outcomes Response to Pembro in Black Patients w/ NSCLCRecruitingNCT06745882Phase 2 Report a problem
Pembrolizumab + Chemotherapy in Newly Diagnosed PCNSLRecruitingNCT06475235Phase 1 Report a problem
Measuring if Immunotherapy Plus Chemotherapy is Better Than Chemotherapy Alone for Patients With Aggressive Poorly Differentiated SarcomasRecruitingNCT06422806Phase 3 Report a problem
Safety and Efficacy of Pembrolizumab in Combination With FLOT About Gastroesophageal Junction Cancer:Not yet recruitingNCT06411171Phase 3 Report a problem
Neoadjuvant Triple Therapy for (Borderline) Resectable Pancreatic Cancer (PREOPANC-5)RecruitingNCT06384560Phase 1/2 Report a problem
MT2022-60: Ph 2 Study of Pembro+ BEAM With ASCT for Relapsed Hodgkin LymphomaRecruitingNCT06377540Phase 2 Report a problem
Pembrolizumab in Progressive Multifocal Leukoencephalopathy (PML) in Immunocompromised Patients Without HIV InfectionNot yet recruitingNCT06276504Phase 2/3 Report a problem
Evaluating the Efficacy and Safety of Pembrolizumab Plus Standard Chemotherapy in the Neoadjuvant Treatment of Local Advanced (LA) HNSCCRecruitingNCT06102395Phase 3 Report a problem
NeoAdj. Therapy Comparing Sacituzumab Govitecan (SG) vs. SG+Pembrolizumab in Low-risk, Triple-neg. EBC (ADAPT-TN-III)RecruitingNCT06081244Phase 3 Report a problem
Exploratory Single-arm, Single-center Adjuvant Treatment of Stage IIIB-IIIC Gastric Cancer With Combination of Palizumab and SOX RegimenRecruitingNCT06036745Phase 2 Report a problem
A Single-Arm Study of Pembrolizumab With Gemcitabine and Cisplatin as Perioperative Therapy for Potentially Resectable Intrahepatic CholangiocarcinomaRecruitingNCT05967182Phase 2 Report a problem
Pembro Plus CAR T-cell Therapy in R/R in PMBCLRecruitingNCT05934448Phase 2 Report a problem
Pembrolizumab in Locally Advanced Sinonasal CarcinomaRecruitingNCT05925491Phase 2 Report a problem
Preoperative Pembrolizumab and Chemotherapy in Resectable, Recurrent HNSCCRecruitingNCT05726370Phase 2 Report a problem
Maintenance Pembrolizumab at Usual or Low doSE in Non-squamous Lung Cancer: a Non-inferiority StudyRecruitingNCT05692999Phase 3 Report a problem
Pembrolizumab Plus Chemo in Neoadjuvant Treatment of Esophageal Squamous Cell Carcinoma (Eastern Cooperative Thoracic Oncology Projects 2004, ECTOP-2004)RecruitingNCT05281003Phase 2 Report a problem
Axitinib +/- Pembrolizumab in First Line Treatment of mPRCCRecruitingNCT05096390Phase 2 Report a problem
A Randomised Open-label Phase III Trial of REduced Frequency Pembrolizumab immuNothErapy for First-line Treatment of Patients With Advanced Non-small Cell Lung Cancer (NSCLC)RecruitingNCT05085028Phase 3 Report a problem
Study of Palliative Radiation Combined with Pembrolizumab in Unresectable Metastatic Stage IV Breast CancerRecruitingNCT04990921Phase 2 Report a problem
Study of Pembrolizumab Combined with Chemotherapy in the First Line Therapy for R/M HNSCC in ChinaRecruitingNCT04857164Phase 2 Report a problem
Addition of Pembrolizumab to the Standard of Care Chemotherapy in Patient With SCCOHTRecruitingNCT04602377Phase 2 Report a problem
Sacituzumab Govitecan +/- Pembrolizumab in Metastatic TNBCRecruitingNCT04468061Phase 2 Report a problem
A Study of Pembrolizumab Plus Local Chemotherapy Using Isolated Limb Infusion (ILI) for Patients With Sarcoma in the Arm or LegRecruitingNCT04332874Phase 2 Report a problem
Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])RecruitingNCT04267848Phase 3 Report a problem
Chemotherapy and Immunotherapy as Treatment for MSS Metastatic Colorectal Cancer With High Immune InfiltrateRecruitingNCT04262687Phase 2 Report a problem
Pembrolizumab in Combination With Chemotherapy and Image-Guided Surgery for Malignant Pleural Mesothelioma (MPM)RecruitingNCT03760575Phase 1 Report a problem
Phase II Study of Second- Line Pembrolizumab Plus GVD for Relapsed or Refractory Hodgkin LymphomaRecruitingNCT03618550Phase 2 Report a problem
A Phase 2 Trial for Metastatic Melanoma Using Adoptive Cell Therapy With Tumor Infiltrating Lymphocytes Plus IL-2 Either Alone or Following the Administration of PembrolizumabRecruitingNCT02621021Phase 2 Report a problem
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)-Japan ExtensionActive, not recruitingNCT06212752Phase 3Results posted Report a problem
A Study of Participant Reported Preference for Subcutaneous Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) Over Intravenous Pembrolizumab (MK-3475) Formulation in Multiple Tumor Types (MK-3475A-F11)Active, not recruitingNCT06099782Phase 2Results posted Report a problem
A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)Active, not recruitingNCT05722015Phase 3Results posted Report a problem
A Phase II Study to Evaluate the Efficacy and Safety of Pembrolizumab in Combination With Mitotane in Patients With Advanced Adrenocortical CarcinomaTerminatedNCT05634577Phase 2Results posted Report a problem
Pembrolizumab/Placebo Plus Paclitaxel With or Without Bevacizumab for Platinum-resistant Recurrent Ovarian Cancer (MK-3475-B96/KEYNOTE-B96/ENGOT-ov65).Active, not recruitingNCT05116189Phase 3Results posted Report a problem
Study of Safety and Efficacy of Pembrolizumab and Chemotherapy in Participants With Newly Diagnosed Classical Hodgkin Lymphoma (cHL) (MK-3475-C11/KEYNOTE-C11)CompletedNCT05008224Phase 2Results posted Report a problem
Pembro+Chemo in Brain MetsTerminatedNCT04964960Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participants With Metastatic Squamous or Nonsquamous Non-Small Cell Lung Cancer (NSCLC) (MK-3475-A86)CompletedNCT04956692Phase 3Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)-China ExtensionCompletedNCT04934722Phase 3Results posted Report a problem
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)-China Extension StudyCompletedNCT04924062Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)-China ExtensionTerminatedNCT04907227Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)-China ExtensionCompletedNCT04882241Phase 3Results posted Report a problem
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)CompletedNCT04489888Phase 4Results posted Report a problem
Sacituzumab Govitecan +/- Pembrolizumab In HR+ / HER2 - MBCActive, not recruitingNCT04448886Phase 2Results posted Report a problem
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder CancerCompletedNCT04383743Phase 2Results posted Report a problem
BLAST MRD AML-2: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 2- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Azacitidine and Venetoclax as Frontline Therapy in Unfit Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04284787Phase 2Results posted Report a problem
Pembrolizumab in MarginalzoneLymphoma A MULTICENTER OPEN LABEL SINGLE-ARM PHASE II STUDYTerminatedNCT04268277Phase 2Results posted Report a problem
Pembrolizumab + Paclitaxel in HR+/HER2- Non-luminal (by PAM50) Advanced Breast Cancer After CDK4/6 Inhibitor ProgressionTerminatedNCT04251169Phase 2Results posted Report a problem
Study of Chemoradiotherapy With or Without Pembrolizumab (MK-3475) For The Treatment of Locally Advanced Cervical Cancer (MK-3475-A18/KEYNOTE-A18/ENGOT-cx11/GOG-3047)CompletedNCT04221945Phase 3Results posted Report a problem
BLAST MRD AML-1: BLockade of PD-1 Added to Standard Therapy to Target Measurable Residual Disease in Acute Myeloid Leukemia 1- A Randomized Phase 2 Study of Anti-PD-1 Pembrolizumab in Combination With Intensive Chemotherapy as Frontline Therapy in Patients With Acute Myeloid LeukemiaActive, not recruitingNCT04214249Phase 2Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) Plus Enzalutamide Plus Androgen Deprivation Therapy (ADT) Versus Placebo Plus Enzalutamide Plus ADT in Participants With Metastatic Hormone-Sensitive Prostate Cancer (mHSPC) (MK-3475-991/KEYNOTE-991)TerminatedNCT04191096Phase 3Results posted Report a problem
A Study of Pembrolizumab in Combination With Cisplatin and Pemetrexed in Advanced Malignant Pleural Mesothelioma (MPM) (MK-3475-A17)CompletedNCT04153565Phase 1Results posted Report a problem
Pembrolizumab (MK-3475) Plus Gemcitabine/Cisplatin Versus Placebo Plus Gemcitabine/Cisplatin for First-Line Advanced and/or Unresectable Biliary Tract Carcinoma (BTC) (MK-3475-966/KEYNOTE-966)CompletedNCT04003636Phase 3Results posted Report a problem
Study of Pemetrexed+Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Participants With First Line Metastatic Nonsquamous Non-small Cell Lung Cancer (MK-3475-189/KEYNOTE-189)-Japan Extension StudyCompletedNCT03950674Phase 3Results posted Report a problem
Testing the Addition of the Immunotherapy Drug Pembrolizumab to the Usual Chemotherapy Treatment (Paclitaxel and Carboplatin) in Stage III-IV or Recurrent Endometrial CancerActive, not recruitingNCT03914612Phase 3Results posted Report a problem
A Study of Carboplatin-Paclitaxel/Nab-Paclitaxel Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With First Line Metastatic Squamous Non-small Cell Lung Cancer (MK-3475-407/KEYNOTE-407)-China Extension StudyCompletedNCT03875092Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921)CompletedNCT03834506Phase 3Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Enzalutamide Versus Placebo Plus Enzalutamide in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-641/KEYNOTE-641)TerminatedNCT03834493Phase 3Results posted Report a problem
Study of Pembrolizumab Given Prior to Surgery and in Combination With Radiotherapy Given Post-surgery for Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-689)Active, not recruitingNCT03765918Phase 3Results posted Report a problem
IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC)CompletedNCT03753659Phase 2Results posted Report a problem
Neoadjuvant Her2-targeted Therapy and Immunotherapy With Pembrolizumab [IIT2018-04-MCARTHUR-NEOHP]Active, not recruitingNCT03747120Phase 2Results posted Report a problem
Safety and Efficacy of Lenvatinib (E7080/MK-7902) in Combination With Pembrolizumab (MK-3475) Versus Lenvatinib as First-line Therapy in Participants With Advanced Hepatocellular Carcinoma (MK-7902-002/E7080-G000-311/LEAP-002)CompletedNCT03713593Phase 3Results posted Report a problem
Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-859/KEYNOTE-859)CompletedNCT03675737Phase 3Results posted Report a problem
Biomarkers of Response to Pembrolizumab Combined With Chemotherapy in Non-Small Cell Lung Cancer (KEYNOTE-782, MK-3475-782)CompletedNCT03664024Phase 2Results posted Report a problem
Pembrolizumab and Reirradiation in Bevacizumab Naïve and Bevacizumab Resistant Recurrent GlioblastomaCompletedNCT03661723Phase 2Results posted Report a problem
Neoadjuvant Phase II Study of Pembrolizumab And Carboplatin Plus Docetaxel in Triple Negative Breast CancerActive, not recruitingNCT03639948Phase 2Results posted Report a problem
Efficacy and Safety Study of First-line Treatment With Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Women With Persistent, Recurrent, or Metastatic Cervical Cancer (MK-3475-826/KEYNOTE-826)CompletedNCT03635567Phase 3Results posted Report a problem
A Trial of Pembrolizumab in Combination With Chemotherapy and Radiotherapy in Stage III NSCLC (KEYNOTE-799, MK-3475-799)CompletedNCT03631784Phase 2Results posted Report a problem
Pembrolizumab/Placebo Plus Trastuzumab Plus Chemotherapy in Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Advanced Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-811/KEYNOTE-811)CompletedNCT03615326Phase 3Results posted Report a problem
Pembrolizumab With Combination Chemotherapy in Treating Participants With Locally Advanced or Metastatic Small Cell/Neuroendocrine Cancers of Urothelium or ProstateActive, not recruitingNCT03582475Phase 1Results posted Report a problem
Study of Pemetrexed + Platinum Chemotherapy With or Without Pembrolizumab (MK-3475) in Adults With Tyrosine Kinase Inhibitor- (TKI)-Resistant Epidermal Growth Factor Receptor- (EGFR)-Mutated Metastatic Non-squamous Non-small Cell Lung Cancer (NSCLC) (MK-3475-789/KEYNOTE-789)CompletedNCT03515837Phase 3Results posted Report a problem
Pembrolizumab, Ixazomib Citrate, and Dexamethasone in Treating Patients With Relapsed Multiple MyelomaCompletedNCT03506360Phase 2Results posted Report a problem
Efficacy and Safety of Pembrolizumab (MK-3475) With Platinum Doublet Chemotherapy as Neoadjuvant/Adjuvant Therapy for Participants With Resectable Stage II, IIIA, and Resectable IIIB (T3-4N2) Non-small Cell Lung Cancer (MK-3475-671/KEYNOTE-671)Active, not recruitingNCT03425643Phase 3Results posted Report a problem
Study Testing The Safety and Efficacy of Adjuvant Temozolomide Plus TTFields (Optune®) Plus Pembrolizumab in Patients With Newly Diagnosed Glioblastoma (2-THE-TOP)Active, not recruitingNCT03405792Phase 2Results posted Report a problem
Study of Pembrolizumab Following TACE in Primary Liver CarcinomaCompletedNCT03397654Phase 1/2Results posted Report a problem
Safety and Efficacy of Pembrolizumab (MK-3475) in Combination With TS-1+Cisplatin or TS-1+Oxaliplatin as First Line Chemotherapy in Gastric Cancer (MK-3475-659/KEYNOTE-659)CompletedNCT03382600Phase 2Results posted Report a problem
Combination Pembrolizumab, Chemotherapy and Bevacizumab in Patients With Cervical CancerTerminatedNCT03367871Phase 2Results posted Report a problem
Pembrolizumab in Metastatic Castration Resistant Prostate Cancer (mCRPC) With or Without DNA Damage Repair DefectsCompletedNCT03248570Phase 2Results posted Report a problem
Pembrolizumab Plus Chemotherapy in NSCLC With Targetable Genetic Alterations After Progression on Targeted AgentsCompletedNCT03242915Phase 2Results posted Report a problem
PET-Directed Therapy With Pembrolizumab and Combination Chemotherapy in Treating Patients With Previously Untreated Classical Hodgkin LymphomaActive, not recruitingNCT03226249Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy in Participants With Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma (MK-3475-585/KEYNOTE-585)CompletedNCT03221426Phase 3Results posted Report a problem
Pembrolizumab and Carboplatin in Treating Patients With Circulating Tumor Cells Positive Metastatic Breast CancerCompletedNCT03213041Phase 2Results posted Report a problem
Pembrolizumab, Chemotherapy, and Radiation Therapy With or Without Surgery in Treating Patients With Anaplastic Thyroid CancerCompletedNCT03211117Phase 2Results posted Report a problem
Pembrolizumab and Standard Therapy in Treating Patients With GlioblastomaActive, not recruitingNCT03197506Phase 2Results posted Report a problem
First-line Esophageal Carcinoma Study With Pembrolizumab Plus Chemo vs. Chemo (MK-3475-590/KEYNOTE-590)CompletedNCT03189719Phase 3Results posted Report a problem
Blinatumomab & Pembrolizumab for Adults With Relapsed/Refractory B-cell ALL With High Marrow LymphoblastsCompletedNCT03160079Phase 1/2Results posted Report a problem
Pembrolizumab-based Therapy in Previously Treated High Grade Neuroendocrine CarcinomasCompletedNCT03136055Phase 2Results posted Report a problem
Pembrolizumab, a Monoclonal Antibody Against PD-1, in Combination With Capecitabine and Oxaliplatin (CAPOX) in People With Advanced Biliary Tract Carcinoma (BTC)CompletedNCT03111732Phase 2Results posted Report a problem
Pembrolizumab With Carboplatin Compared to Carboplatin Alone in Breast Cancer Patients With Chest Wall DiseaseCompletedNCT03095352Phase 2Results posted Report a problem
Study Evaluating the Addition of Pembrolizumab to Radium-223 in mCRPCCompletedNCT03093428Phase 2Results posted Report a problem
Pembrolizumab and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin LymphomaActive, not recruitingNCT03077828Phase 2Results posted Report a problem
A Study of Pembrolizumab (MK-3475) in Combination With Etoposide/Platinum (Cisplatin or Carboplatin) for Participants With Extensive Stage Small Cell Lung Cancer (MK-3475-604/KEYNOTE-604)CompletedNCT03066778Phase 3Results posted Report a problem
A Randomized Phase II Study Of Eribulin Mesylate With or Without Pembrolizumab For Metastatic Hormone Receptor Positive Breast CancerCompletedNCT03051659Phase 2Results posted Report a problem
Pembrolizumab and Capecitabine in Treating Patients With Locally Advanced or Metastatic Triple Negative or Hormone-Refractory Breast Cancer That Cannot Be Removed by SurgeryStatus unknownNCT03044730Phase 2Results posted Report a problem
Study of Pembrolizumab (MK-3475) or Placebo With Chemoradiation in Participants With Locally Advanced Head and Neck Squamous Cell Carcinoma (MK-3475-412/KEYNOTE-412)CompletedNCT03040999Phase 3Results posted Report a problem

← Pembrolizumab